Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained
How the Novo Nordisk Board Built a Weight-Loss Drug Empire
Episode 110 dives into the Novo Nordisk boardroom to explore how a Danish insulin company became the most valuable business in Europe, driven by Ozempic and Wegovy. Lucas and Luna unpack the board's unusual stability — most directors have served over a decade — and how that continuity let them bet big on GLP-1 science when others hesitated. They trace the 2014 decision to fund a Phase 3 trial for semaglutide at a time when obesity was still a niche market, and how the board's controlling shareholder structure, the Novo Nordisk Foundation, insulated them from short-term activist…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.